lung cancer
Conditions
Interventions
Treatment group:According to the 2024 CSCO Guidelines for the Diagnosis and Treatment of Non Small Cell Lung Cancer, the combination of Western medicine standardized treatment for NSCLC stage IV and t
Formula for Suppressing Lung Drink: 30g of Radix Ginseng, 30g of Coix seed, 12g of Polygonatum sibiricum, 30g of Angelica sinensis, 5 centipedes, 9g of Pinellia ternata, 18g of Buckwheat, 30g of Reed
control group:According to the 2024 CSCO Guidelines for Diagnosis and Treatment of Non Small Cell Lung Cancer, NSCLC stage IV is treated with standardized Western medicine for a total of three treatme
Sponsors
Tongde Hospital of Zhejiang Provincial
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1) Diagnosed with non-small cell lung cancer through organizational or cellular pathology, according to the American Joint Committee on Cancer Classification (AJCC) lung cancer TNM stage IV (8th edition); 2) Dialectical classification includes Qi Yin deficiency and phlegm toxin stasis type; 3) According to RECIST 1.1 standards, there must be at least one measurable lesion; 4) The patient's survival period is not less than 6 months and the ECOG score is 0-2 points; 5) The patient's gender is not limited, and their age ranges from 18 to 75 years old; 6) Those who have not participated in clinical trials of other drugs within 3 months and have not taken any other traditional Chinese medicine orally within 1 month before treatment; 7) No major organ dysfunction, with basic normal heart, liver, and kidney function; No other history of cancer; 8) Those who agree to participate in this study and sign the informed consent form are expected to have good compliance and cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1) Patients who have received traditional Chinese medicine treatment in the past month; 2) Individuals with severe impairment of heart, liver, kidney, and lung function or diseases of the hematopoietic system; 3) Pregnant or lactating patients; 4) For patients with poor compliance with the protocol and difficulty in follow-up, the researchers believe that they are not suitable to participate in this trial; 5) Individuals who are allergic to drugs or are currently participating in other drug trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate and disease control rate of solid tumor efficacy evaluation based on RECIST 1.1; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life;Tumor indicators such as CEA, SCC, CyFRA211;Kaplan Meier method was used to calculate overall survival rate and progression free survival;Evaluating lung cancer prognosis based on CT imaging AI prediction model;Traditional Chinese Medicine Syndrome Points; | — |
Countries
China
Contacts
Public Contactzhouying
Tongde Hospital of Zhejiang Provincial
Outcome results
None listed